Tuesday, November 12, 2013, 3:00 p.m. - 3:55 p.m., Room 405
With capital markets opening up, 2013 saw 38 (and counting) new biotech IPOs – many of which are staying strong even after their initial debut. Will this excitement continue onto 2014 and translate into new opportunities for China? This panel will explore the state of the capital markets in China in comparison to the exciting new developments in the U.S. through the prism of biotech insiders, as well as assess the current and future attractiveness of local IPOs, providing a global and insightful perspective to both companies and investors.
- John V. Oyler, Founder and CEO, BeiGene
- Howard Liang, PhD, Managing Director, Biotechnology Equity Research, Leerink Swann
- David Thomas, CFA, Director, Industry Research & Analysis, BIO
- Asish K. Xavier, PhD, Vice President, Venture Investments, J&J Development Corporation